Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

ClinicalTrials.gov ID: NCT03385239

Public ClinicalTrials.gov record NCT03385239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.

Study identification

NCT ID
NCT03385239
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Akcea Therapeutics
Industry
Enrollment
114 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 29, 2018
Primary completion
Nov 24, 2019
Completion
Feb 24, 2020
Last update posted
Jan 10, 2023

2018 – 2020

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Clinical Site Cottonwood Arizona 86326
Clinical Site Little Rock Arkansas 72205
Clinical Site Carmichael California 95608
Clinical Site Fresno California 93720
Clinical Site La Jolla California 92037-7410
Clinical Site Long Beach California 90807
Clinical Site Montclair California 91763
Clinical Site Wilmington Delaware 19803
Clinical Site Boca Raton Florida 33434
Clinical Site Jacksonville Florida 32216
Clinical Site New Port Richey Florida 34652
Clinical Site Munster Indiana 46321
Clinical Site Ames Iowa 50010
Clinical Site Kansas City Kansas 66160
Clinical Site Louisville Kentucky 40213
Clinical Site Fall River Massachusetts 02721
Clinical Site Cooperstown New York 13326
Clinical Site High Point North Carolina 27262
Clinical Site Portland Oregon 97239
Clinical Site Lansdale Pennsylvania 19446
Clinical Site Providence Rhode Island 02906
Clinical Site Greer South Carolina 29651
Clinical Site Houston Texas 77030
Clinical Site Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03385239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2023 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03385239 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →